Simplify Logo

Full-Time

Clinical PK Manager

Clinical Pharmacology

Confirmed live in the last 24 hours

Revolution Medicines

Revolution Medicines

201-500 employees

Develops targeted therapies for RAS cancers

Hardware
Biotechnology
Healthcare

Compensation Overview

$120k - $158kAnnually

+ Equity Awards + Benefits + Learning and Development Opportunities

Senior, Expert

San Carlos, CA, USA

Category
Healthcare Administration & Support
Nursing & Allied Health Professionals
Medical, Clinical & Veterinary
Required Skills
Communications
Requirements
  • MS in Analytical Chemistry, Pharmacokinetics, drug metabolism or a related scientific discipline with 5 years of relevant industry experience, or BS with over 8 years of relevant industry experience.
  • In-depth knowledge and hands-on experience with LC/MS/MS and quantitative analysis of small molecules in complex biological matrices.
  • Good understanding of regulatory guidelines for regulated bioanalysis.
  • Prior experience in non-compartmental PK analysis using Phoenix WinNonlin.
  • Excellent interpersonal, oral, and written communication skills.
  • Thrives in a collaborative team setting and is driven by a desire to be innovative in a high energy, small company environment.
Responsibilities
  • Liaise with Clinical Pharmacology Project Leads to design and review the pharmacokinetics components of a clinical protocol, lab manual and other study-associated documents.
  • Manage and provide technical oversight to bioanalytical CROs on regulated bioanalysis.
  • Facilitate clinical PK sample reconciliation and manage sample analysis timeline.
  • Review method validation protocols, PK sample analysis plans and study reports.
  • Review pharmacokinetic concentration data, conduct non-compartmental PK analysis, summarize data and present at project team meetings to drive critical study decisions.
  • Manage collaboration with clinical pharmacology CROs/consultants to support PK analysis for clinical study reports and relevant sections of regulatory filing documents.

Revolution Medicines develops targeted treatments for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main products are RASON Inhibitors, designed to inhibit the activity of RAS proteins that promote cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses specifically on RAS-driven cancers, allowing them to carve out a niche in the oncology market. Their goal is to transform cancer treatment by providing effective therapies for patients suffering from these challenging conditions.

Company Stage

IPO

Total Funding

$1.3B

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

12%

1 year growth

40%

2 year growth

111%
Simplify Jobs

Simplify's Take

What believers are saying

  • The acquisition of EQRx is expected to add over $1 billion in net cash, significantly bolstering Revolution Medicines' financial position.
  • Successful public offerings and underwriters' full exercise of options have brought substantial capital, indicating strong investor confidence.
  • The company's innovative RASON Inhibitors and Tri Complex Inhibitor platform have the potential to revolutionize treatment for RAS-driven cancers, offering significant clinical impact.

What critics are saying

  • The highly specialized focus on RAS-driven cancers may limit market size and revenue potential compared to broader oncology companies.
  • Integration challenges from the acquisition of EQRx could divert focus and resources, potentially impacting ongoing projects.

What makes Revolution Medicines unique

  • Revolution Medicines focuses exclusively on RAS-driven cancers, a niche but critical area in oncology, unlike broader-spectrum oncology companies.
  • Their Tri Complex Inhibitor platform allows for highly specialized treatments, setting them apart from competitors with more generalized approaches.
  • The company's revenue model, which includes licensing, co-development partnerships, and direct sales, provides multiple revenue streams, enhancing financial stability.